Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 151-158

  Duncan, Christine N ^a   Majhail, Navneet S ^b   Brazauskas, Ruta ^c   Wang, Zhiwei ^c   Cahn, Jean Yves ^d   Frangoul, Haydar A ^e   Hayashi, Robert J ^f   Hsu, Jack W ^g   Kamble, Rammurti T ^h   Kasow, Kimberly A ⁱ   Khera, Nandita ^j   Lazarus, Hillard M ^k   Loren, Alison W ^l   Marks, David I ^m   Maziarz, Richard T ⁿ   Mehta, Paulette ^o,p   Myers, Kasiani C ^q   Norkin, Maxim ^g   Pidala, Joseph A ^r   Porter, David L ^l   Reddy, Vijay ^s   Saber, Wael ^c   Savani, Bipin N ^t   Schouten, Harry C ^u   Steinberg, Amir ^v   Wall, Donna A ^w,x   Warwick, Anne B ^y   Wood, William A ⁱ   Yu, Lolie C ^z   Jacobsohn, David A ^aa   Sorror, Mohamed L ^ab,ac   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h CENTER FOR CELL AND GENE THERAPY   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^p UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^q CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^t VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^u MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^v MOUNT SINAI HOSPITAL   (United States)

^w Cellular Therapy Laboratory   (Canada)

^x UNIVERSITY OF MANITOBA   (Canada)

^y UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^z LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^aa CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^ab USA   (United States)

^ac UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Allogeneic transplantation; Hematopoietic cell transplantation; Late effects; Long term survival; Second transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER SURVIVOR; CATARACT; CEREBROVASCULAR ACCIDENT; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; FEMALE; GONAD DYSFUNCTION; GROWTH DISORDER; HUMAN; HYPOTHYROIDISM; INFECTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LONG TERM SURVIVAL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; MOUTH CANCER; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; SARCOMA; SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION; SEIZURE; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; ADOLESCENT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; OSTEONECROSIS; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SURVIVAL ANALYSIS; TIME FACTOR; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT;

ADOLESCENT; ADULT; AGED; CATARACT; CHILD; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; OSTEONECROSIS; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927168704     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.006     Document Type: Article

References (34)

1. Bosi A., Laszlo D., Labopin M., et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. JClin Oncol 2001, 19:3675-3684.
2. Shaw B.E., Mufti G.J., Mackinnon S., et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008, 42:783-789.
3. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
4. Arellano M.L., Langston A., Winton E., et al. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007, 13:116-123.
5. Poon L.M., Bassett R., Rondon G., et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 2013, 48:666-670.
6. Spyridonidis A., Labopin M., Schmid C., et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012, 26:1211-1217.
7. Fielding A.K., Richards S.M., Chopra R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
8. Fathi A.T., Chen Y.B. Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Curr Hematol Malig Rep 2014, 9:186-192.
9. Michallet M., Tanguy M.L., Socie G., et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000, 108:400-407.
10. Arfons L.M., Tomblyn M., Rocha V., Lazarus H.M. Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol 2009, 16:112-123.
11. Meshinchi S., Leisenring W.M., Carpenter P.A., et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2003, 9:706-713.
12. Pawson R., Potter M.N., Theocharous P., et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG+/- Ida) and second allogeneic stem cell transplant. Br J Haematol 2001, 115:622-629.
13. Kato M., Horikoshi Y., Okamoto Y., et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant 2012, 47:1307-1311.
14. Blau I.W., Basara N., Bischoff M., et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000, 25:41-45.
15. Eapen M., Giralt S.A., Horowitz M.M., et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.
16. Patel S.A., Coulter D.W., Grovas A.C., et al. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia. JPed Hematol Oncol 2014, 36:491-494.
17. Hosing C., Saliba R.M., Shahjahan M., et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005, 36:157-162.
18. Kedmi M., Resnick I.B., Dray L., et al. Aretrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009, 15:483-489.
19. Armenian S.H., Sun C.L., Kawashima T., et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011, 118:1413-1420.
20. Sun C.L., Francisco L., Kawashima T., et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010, 116:3129-3139. quiz 3377.
21. Sun C.L., Kersey J.H., Francisco L., et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. Biol Blood Marrow Transplant 2013, 19:1073-1080.
22. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
23. Kishi K., Takahashi S., Gondo H., et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997, 19:461-466.
24. Bosi A., Bacci S., Miniero R., et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia 1997, 11:420-424.
25. Christopeit M., Kuss O., Finke J., et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. JClin Oncol 2013, 31:3259-3271.
26. Kishi K., Hiasa Y., Tanaka H., et al. Identification of predictive factors associated with recurrent restenosis after second percutaneous transluminal coronary angioplasty [Japanese]. JCardiol 1997, 29:7-12.
27. Radich J.P., Sanders J.E., Buckner C.D., et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. JClin Oncol 1993, 11:304-313.
28. Nagler A., Or R., Naparstek E., et al. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000, 28:1096-1104.
29. Mrsic M., Horowitz M.M., Atkinson K., et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992, 9:269-275.
30. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
31. Baker K.S., Ness K.K., Weisdorf D., et al. Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 2010, 24:2039-2047.
32. Gifford G., Sim J., Horne A., Ma D. Health status, late effects and long term survivorship of allogeneic bone marrow transplantation: a retrospective study. Int Med J 2014, 44:139-147.
33. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:337-341.
34. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:348-371.